FDA opens up electronic communication for companies
This article was originally published in Clinica
Executive Summary
The US FDA has updated its practices for communicating with industry to allow device reviewers to respond to companies via fax and email. The March 1 Blue Book Memo, which outlines the changes, says they will provide a "fair and consistent" approach to what the agency says is now the ubiquitous use of electronic communications. It also will help reduce the paperwork burden on industry in the spirit of the much-touted least burdensome provision of the 1997 FDA Modernization Act, the agency said.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.